# A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

> **NCT02857868** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** ABL001

## Key facts

- **NCT ID:** NCT02857868
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-03
- **Primary completion:** 2017-07-20
- **Final completion:** 2017-07-20
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02857868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02857868, "A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02857868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*